The Max Foundation Renews and Expands Agreement with Incyte
The Max Foundation is proud to announce it has signed a renewed collaboration agreement with Incyte – a dedicated pharmaceutical partner and member of our humanitarian pact.
Since February 2017, Incyte has partnered with The Max Foundation to assist patients with cancer in Central Asia and Eastern Europe who are in need and unable to access treatment. The renewal by Incyte will allow The Max Foundation, through our drug donation program Max Access Solutions, to expand the number of patients who may be eligible to receive treatment with Iclusig (ponatinib) from 35 to up to 50 at no cost for as long as needed.
“As we work to expand treatment access for patients in low-income countries, we are grateful to have committed partners like Incyte,” said Pat Garcia-Gonzalez, CEO and co-founder of The Max Foundation. “We’re so excited to not only continue our collaboration, but also to expand its size and bring effective medicine to more patients in need.”
“At Incyte we are fully aligned with the mission of The Max Foundation, focused on increasing patient access to care, support, and treatment,” added Jonathan Dickinson, General Manager of Incyte in Europe. “We are proud to be part of a program dedicated to making cancer treatments available to appropriate patients in Central Asia and Eastern Europe. We are happy and privileged to partner with and support to The Max Foundation’s efforts and look forward to another year of making a difference for patients with cancer.”
We at The Max Foundation express our thanks to Incyte for their continued collaboration, and will keep an ear out for the Incyte Bell (pictured below, and rung once each week for each new patient treated).
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
Welcoming Dr. Michael J. Wagner, MD, to The Max Foundation’s Medical Advisory Board
The Max Foundation is thrilled to welcome Dr. Michael J. Wagner to our Gastrointestinal Stromal Tumor (GIST) Medical Advisory Board. Since we met Dr. Wagner in early 2020 at a GIST patient meeting in Seattle, he has provided our program with invaluable training and support. “Dr. Wagner has gone above and beyond in advising our….
New study confirms an excellent survival rate of cancer patients in a medication donation program
A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.
The Max Foundation (Max) Expands Board and Global Team to Advance Mission of Accelerating Health Equity
Max adds three new members to the Board of Directors, increasing the seats from eight to 11 In addition, Max has added 10 new team members in 2024 to support growing patient reach, collaboration with partners, and new disease areas This expansion will ensure Max can meet its strategic goals, including treating more patients, amplifying….
The Max Foundation uses cookies to improve your experience on our site. Please read our Privacy Policy for more information.Dismiss